Reneo Pharmaceuticals, (id:6676 RPHM)
15.55 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:56:16 PM)
Exchange closed, opens in 1 day 10 hours
-3.42 USD (-3.42%)
-2.87 USD (-2.87%)
-13.61 USD (-13.61%)
-6.33 USD (-6.33%)
-75.08 USD (-75.08%)
-89.84 USD (-89.84%)
About Reneo Pharmaceuticals,
Market Capitalization 60.84M
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
| Headquarters (address) |
18575 Jamboree Road Irvine 92612 CA United States |
| Phone | 858 283 0280 |
| Website | https://reneopharma.com |
| Employees | 8 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | RPHM |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 9.80 - 77.60 |
| Market Capitalization | 60.84M |
| P/E trailing | -6.17 |
| P/E forward | -47.89 |
| Price/Book | 0.791 |
| Beta | 0.220 |
| EPS | -16.80 |
| EPS United States (ID:6, base:3403) | 24.22 |